Nuzenio

Sab Biotherapeutics Inc

Sab Biotherapeutics Inc news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 16 latest news signals 8 publisher sources 100/100 entity strength

Latest news

H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $10 - MoomooMoomoo · Sat, 08 Aug 2026 10:22:56 GMT SAB Biotherapeutics, Inc. (SABS) Stock Price, News, Quote & History - Yahoo! Finance CanadaYahoo! Finance Canada · Fri, 07 Aug 2026 17:38:47 GMT SAB Biotherapeutics Q2 Earnings Call Highlights - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 12:03:53 GMT SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... - Yahoo FinanceYahoo Finance · Thu, 06 Aug 2026 23:14:21 GMT SAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 13:32:43 GMT SAB Biotherapeutics, Inc. Q2 2026: Net loss $(22.5M), EPS $(0.28) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 12:01:01 GMT SAB BIO Reports Q2 2026 Results, Expands SAB-142 Type 1 Diabetes Trials and Secures Breakthrough T1D Grant for PRISE-hATG Study - Quiver QuantitativeQuiver Quantitative · Thu, 06 Aug 2026 11:44:00 GMT Press Release: SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - MoomooMoomoo · Thu, 06 Aug 2026 11:30:00 GMT

Timeline

Sat, 08 Aug 2026 10:22:56 GMTH.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $10 - Moomoo

Fri, 07 Aug 2026 17:38:47 GMTSAB Biotherapeutics, Inc. (SABS) Stock Price, News, Quote & History - Yahoo! Finance Canada

Fri, 07 Aug 2026 12:03:53 GMTSAB Biotherapeutics Q2 Earnings Call Highlights - Yahoo Finance

Thu, 06 Aug 2026 23:14:21 GMTSAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... - Yahoo Finance

Thu, 06 Aug 2026 13:32:43 GMTSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView

Thu, 06 Aug 2026 12:01:01 GMTSAB Biotherapeutics, Inc. Q2 2026: Net loss $(22.5M), EPS $(0.28) — 10-Q Summary - TradingView

Related explainers

ElectionsElection stories need careful handling because polls, turnout, legal challenges, and campaign claims can change quickly.HealthHealth stories help readers understand public-health signals, medical research, hospital systems, medicines, disease updates, and safety guidance.HealthcareHealthcare stories can affect personal decisions, so Nuzenio treats them as information that should be checked with original sources and professionals.

Connected entities

SABS15 live mentions Inc12 live mentions SAB Biotherapeutics6 live mentions Biotherapeutics4 live mentions Earnings Call Highlights4 live mentions TradingKey TradingKey4 live mentions Price4 live mentions Chg4 live mentions TradingView SAB Biotherapeutics3 live mentions TradingView3 live mentions

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Sab Biotherapeutics Inc.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

8 distinct publisher/source names are currently connected to this entity page.